In this report, we describe the mechanism of TGF-b receptor type I (RI) repression in the GEO human colon carcinoma cells. Treatment of GEO cells with the DNA methyltransferase inhibitor, 5 azacytidine induced RI expression and restored TGF-b response. A stably transfected RI promoter-reporter construct (RI-Luc) expressed higher activity in the 5 aza C treated GEO cells, suggesting the activation of a transactivator for RI transcription. Gel shift analysis indicated enhanced binding of proteins from the 5 aza C treated nuclear extracts to radiolabeled Sp1 oligonucleotides speci®cally contained in the RI promoter. Protein stability studies after cyclohexamide treatment suggested an increase in the Sp1 protein stability from the 5 aza C treated GEO cells. Further, transfection of Sp1 cDNA into untreated GEO control cells increased RI promoter activity and thus induced RI expression. 5 aza C mediated Sp1 expression in Sp1 de®cient GEO colon and MCF-7 breast cancer cells also enhanced the activity of several other Sp1 dependent promoters such as TGFb receptor type II (RII), Cyclin A and p21/waf1/cip1. These results indicate that restoration of Sp1 in several dierent types of Sp1 de®cient cells leads to enhanced activation of a wide range of Sp1 dependent promoters. Oncogene (2000) 19, 4660 ± 4667.
Introduction
The role of TGF-bs in the regulation of cell proliferation, dierentiation and extracellular matrix (ECM) re-modeling in various cell types has been well documented (Massague, 1990; Roberts and Sporn, 1991) . TGF-b exerts its eects through high anity cell surface receptors, which are referred to as type I (RI), type II (RII) and type III (RIII). While RI and RII are glycoproteins of 53 and 75 kDa, respectively, RIII is a 280 ± 330 kDa proteoglycan (Yingling et al., 1995) . RI and RII are serine/ threonine kinases which form an active heterooligomeric complex and are the key players in the TGF-b mediated signaling cascade (Franzen et al., 1993; Lin et al., 1992; Wrana et al., 1992 Wrana et al., , 1994 . Recent studies indicate that, following TGF-b binding and subsequent activation of RI by RII, RI phosphorylates Smad2 and/or Smad3, which can then associate with Smad4 and translocate to the nucleus where binding to the target DNA or other DNA binding proteins occurs. In contrast, Smad6 as well as Smad7 were found to antagonize the TGF-b signaling pathway by binding to RI and thereby preventing the activation of Smad2 and Smad3 (Attisano and Wrana, 1998) .
One of the pronounced eects of TGF-b is the growth inhibition of normal epithelial as well as some cancer cells. Since RI and RII are vital for TGF-b mediated growth suppression, loss of either receptor may contribute to TGF-b resistance and subsequent tumor progression. Previous work has indicated TGF-b resistance either due to a mutation of the RII gene in gastric and colon carcinoma cells Park et al., 1994; Wang et al., 1995) or transcriptional repression of RII due to decreased binding of nuclear proteins to the RII promoter in keratinocytes and breast cancer cells (Ammanamanchi et al., 1998; Kim et al., 1997) . A signi®cant percentage of gastric and colon cancer cells show loss or reduced expression of RI and/or RII transcript and protein levels without mutation, indicating abnormalities in transcriptional or post-transcriptional regulation of TGF-b receptors may be involved in the absence of TGF-b growth control and its tumor suppressor activities.
Colon carcinoma cells with low levels of RI expression were identi®ed in approximately 20% of the 30 colon carcinoma cell lines screened Wang et al., 1996) . One of these cell lines, designated GEO, was examined in detail and found to be marginally TGF-b sensitive. RI replacement enhanced TGF-b response and reduced tumorigenicity in athymic nude mice (Wang et al., 1996) . In contrast, RII replacement in these cells did not aect TGF-b sensitivity and its other biological properties suggesting that RI is the limiting factor for TGF-b signal transduction in RI de®cient cells (Wang et al., 1996) .
Recent studies indicated DNA methylation as a mode of gene inactivation of several genes including some that are involved in cell cycle control . DNA methyltransferase inhibitors, 5 aza-cytidine (5 aza C) and 5 aza-2'-deoxycytidine (5 aza-2'dc) are the most commonly used DNA demethylating agents to reverse methylation and reactivate the expression of these genes (Jones, 1996) .
The present study was undertaken to delineate the mechanism(s) for reduced RI expression in GEO human colon carcinoma cells. The results presented here indicate that RI is transcriptionally repressed. Transcriptional repression was not due to methylation of the RI promoter but was due to a de®ciency of Sp1 transcriptional activity. Treatment of GEO cells with 5 aza C leads to increased Sp1 steady state levels as a result of increased protein stability and, consequently the induction of RI expression. Also, transfection of Sp1 cDNA into GEO cells led to enhanced RI expression, con®rming further that Sp1 levels/activities are the limiting factor for RI expression in these cells. 5 aza C mediated Sp1 expression also up-regulated activities of several other Sp1 dependent promoters including RII, Cyclin A and p21/waf1/cip1, in GEO as well as other Sp1 de®cient cell lines indicating that Sp1 may be the limiting factor for the expression of a wide variety of Sp1 dependent genes in these cells.
Results

Transcriptional repression of RI
Transcriptional analyses of RI was performed using nuclear run-on assays. The data indicate that RI transcription is down-regulated in GEO cells in comparison to CBS 4 and CBS 9 human colon carcinoma cells (Figure 1 ) which contain typical amounts of RI mRNA for colon carcinoma cells (Wang et al., 1996) .
Effect of 5 aza C on the induction of RI expression
RNase protection assays were performed to determine whether treatment with the DNA methyltransferase inhibitor, 5 aza C leads to expression of RI transcript. Accumulation of RI transcript was observed in the 5 aza C treated GEO cells ( Figure  2 ). Cell surface receptor binding studies with 125 I TGF-b1 were carried out to determine whether increased RI transcript resulted in increased RI protein. The data show that increased RI transcript expression resulted in increased cell surface binding of TGF-b to both RII and RI (Figure 3 ). Increased binding for RIII was also noted. This phenomenon was also observed after RI transfection in GEO cells (Wang et al., 1996) . Binding speci®city was demonstrated by competing with a 50-fold excess of cold TGF-b1.
Responsiveness to TGF-b1
TGF-b-dependent promoter activity was analysed using the p3TP-Lux plasminogen activator inhibitor promoter-TGF-b responsive element in tandem with a luciferase reporter to evaluate whether 5 aza Cmediated RI expression in GEO cells restored TGF-b sensitivity. The TGF-b-responsive promoter-luciferase construct was stably expressed in the GEO cells. Following 5 aza C treatment, cells were subjected to treatment with 5 ng/ml TGF-b1 on day 7 for 24 h, and luciferase activity was then determined (Wrana et al., 1992) . TGF-b had no eect on the control GEO cells, but 5 aza C-treated cells showed two and sixfold induction in the absence and presence of TGF-b1, respectively (Figure 4 ). The increased luciferase activity in the absence of exogenous TGF-b1 re¯ected Figure 1 Low RI transcription in GEO human colon carcinoma cells: RI transcriptional analyses was performed in GEO, CBS 4 and CBS 9 human colon carcinoma control cells using nuclear run-on assays as described under Materials and methods Figure 2 Expression of RI mRNA after 5 aza C treatment: Total RNA was isolated from control and 5 aza C-treated GEO human colon carcinoma cells as described under Materials and methods. RI riboprobe was incubated with 40 mg of total RNA and the hybridized RNA was analysed by RNase protection assay as described under Materials and methods. Actin RNA levels were used for normalization Oncogene RI repression in colon carcinoma S Periyasamy et al increased autocrine TGF-b activity resulting from 5 aza C treatment. This phenomenon has also been noted following RI transfection in GEO cells (Wang et al., 1996) .
RI promoter activity
Southern analysis of the RI promoter region did not reveal any methylated sites (data not shown). We have compared the RI promoter activity in control and 5 aza C treated GEO cells using an RI promoterluciferase reporter construct to examine whether the induction of RI after 5 aza C treatment is caused by the activation of a transactivator. The GEO RI-Luc cells showed higher promoter activity after 5 aza C treatment in comparison to untreated control cells, thus suggesting the activation of nuclear proteins that bind to the RI promoter and enhance its activity ( Figure 5 ). This promoter fragment contains two Sp1 binding sites at 7159 bp and 7347 bp relative to the start site (Bloom et al., 1996) .
EMSAs
To identify the proteins that are enhancing the RI promoter activity in the 5 aza C treated GEO cells, EMSAs were performed using nuclear extracts and the 32 P-labeled oligonucleotides corresponding to two Sp1 binding sites which had been previously identi®ed ( Figure 6a ) (Bloom et al., 1996) . There was enhanced binding of nuclear proteins from the 5 aza C-treated GEO cells to both of the 32 P-labeled oligonucleotides compared with untreated control cells ( Figure 6b ). The mobilities of these complexes were similar to those resulting from recombinant human Sp1 binding to 32 Plabeled Sp1 oligonucleotides complex. Wild-type Sp1 oligonucleotides competed with 32 P-labeled Sp1 oligonucleotides for binding to the protein complexes, whereas the mutant Sp1 oligonucleotide could not, thus indicating the speci®city of the shifts. Supershift assays were carried out by pre-incubating the nuclear extracts with 2 mg of Sp1 antibody prior to the addition of 32 P-labeled oligonucleotides. The low mobility complex was shifted con®rming further that I TGF-b1, cross-linked with 0.33 mM disuccinimyl suberate and separated by 4 ± 10% SDS ± PAGE under reducing conditions. Binding speci®city was demonstrated by 50-fold excess of cold TGF-b1 Figure 4 Restoration of TGF-b response after 5 aza C treatment: GEO and GEO p3TP cells were subjected to 5 aza C treatment as described under Materials and methods. Following 5 aza C treatment the cells were treated for 24 h with 5 ng/ml TGFb1, harvested and luciferase activity was measured and presented as relative units Figure 5 Eect of 5 aza C on the RI promoter activity: GEO control cells and GEO RI-Luc cells were treated with 5 aza C and luciferase activity was measured as described under Materials and methods the enhanced protein-DNA complex contains Sp1 (Figure 6c ). Recombinant human Sp1 (rh Sp1) was used as a positive control.
Effect of 5 aza C on Sp1 transcription
Northern analysis using Sp1 cDNA as a probe was performed to determine whether 5 aza C induces Sp1 transcript levels. Control and 5 aza C-treated GEO cells expressed similar levels of Sp1 mRNA, indicating that demethylation was not aecting Sp1 transcription (data not shown).
Expression of Sp1 protein
To determine whether 5 aza C treatment stimulates Sp1 protein expression, Western immunoblot was performed using 4 mg protein of nuclear extracts from 5 aza C-treated and untreated GEO cells. Western analysis showed two protein species of 95 and 105 kDa. The two species have been previously characterized and are the result of dierential posttranslational modi®cations of the Sp1 polypeptide (Pugh and Tjian, 1990; Shin et al., 1992) . Signi®cant increases of both the species were observed in the 5 aza C-treated GEO cells, whereas there was no change in the c-Jun levels (Figure 7 ). Sp1 protein stability was determined after treatment with 10 mg/ml of cyclohexamide as described previously for this protein (Ammanamanchi et al., 1998) to determine if 5 aza C aects Sp1 protein stability. Sp1 protein from 5 aza Ctreated cells showed enhanced stability compared with untreated GEO control cells (Figure 8 ), thus indicating that the increased steady-state levels of Sp1 protein and oligonucleotide binding were the result of indirect actions of the demethylating agent on Sp1.
Effect of exogenous Sp1 expression on RI promoter activity and transcript levels
To con®rm further that low steady state Sp1 levels contribute to RI repression in GEO cells, we transiently transfected Sp1 cDNA into GEO RI-Luc cells and GEO cells followed by analyses of RI promoter activity and RI transcript levels by luciferase and RNase protection assays, respectively. Sp1 expression increased RI promoter activity (Figure 9a ) as well as RI mRNA expression (Figure 9b ). Total RNA from TGF-b sensitive human colon carcinoma cells, FET was used as a positive control and t-RNA as a negative control.
aza C mediated Sp1 effects on multiple Sp1 dependent promoters
To determine whether the 5 aza C mediated Sp1 eects are restricted to RI promoter and GEO colon carcinoma cells or whether they re¯ect broader control of Sp1 dependent genes, we transiently transfected multiple Sp1 dependent promoters for RII, Cyclin A, p21/waf1/cip1 and a control non-Sp1 dependent pNFkB-Luc construct into untreated and 5 aza Ctreated GEO and MCF-7L cells. While the non-Sp1 dependent pNFkB-Luc construct did not respond to 5 a c b Figure 6 (a) Sequences of the sense strands of double-stranded Sp1 oligonucleotides used for the gel shift analysis. (b) Binding of nuclear proteins to the Sp1 oligonucleotides. EMSA was performed using 32 P-labeled Sp1 oligonucleotides which were allowed to bind to 4 mg of nuclear extracts from the control and 5 aza C-treated GEO cells. Wild-type (wt) and mutant (mt) Sp1 oligonucleotides were used as competitors. (c) Detection of protein-DNA complexes using Sp1 antibody. To con®rm that protein-DNA complexes contained Sp1, supershift assays were carried out by incubating the nuclear extract with 2 mg of Sp1 antibody prior to the addition of 32 P-labeled Sp1 oligonucleotides Figure 7 Western immunoblot analysis of Sp1: Nuclear extracts (4 mg) from control and 5 aza C-treated GEO cells were resolved on a 7.5% SDS ± PAGE, transferred to nitrocellulose membrane, and probed with rabbit anti-human Sp1 and c-Jun antibodies. Sp1 antibody recognizes two protein species of 95 and 105 kDa, which are the result of dierential post-translational modi®cations as described in the text aza C treatment, Sp1 dependent promoters exhibited 4 ± 6-fold increase in their activities (Figure 10a,b) .
Discussion
Colon carcinoma cell lines with low levels of RI expression have been identi®ed Wang et al., 1996) . One of these cell lines, GEO was only marginally responsive to growth inhibition by TGF-b and RI replacement in this cell line restored TGF-b response and reduced tumorigenicity in athymic nude mice (Wang et al., 1996) . However, RII replacement in this cell line did not enhance TGF-b response, suggesting that RI expression but not RII, is the limiting factor for the escape of negative growth regulation by TGF-b. Hence, targeting re-expression of RI may oer potential novel approaches for the treatment or chemoprevention of colon cancer. In this study, we have examined the ability of the DNA methyltransferase inhibitor, 5 aza C to induce endogenous RI expression in the GEO human colon carcinoma cells.
GEO cells treated with 5 aza C expressed RI transcript as well as cell surface protein (Figures 2  and 3 ). Most importantly, 5 aza C mediated RI induction resulted in restoration of TGF-b response (Figure 4) . However, the induction of RI expression after 5 aza C treatment was not due to direct demethylation of the RI gene. This suggested the plausible involvement of increased activation of a transactivator as a cause for enhanced RI transcription. The RI promoter lacks a distinct TATA box, and Sp1 has been reported to play a signi®cant role in the initiation of transcription from promoters lacking distinct TATA boxes (Pugh and Tjian, 1990) . The human RI promoter contains 4 Sp1 sites at 7159, 7347, 7899 and 7954 bps relative to the start site (Bloom et al., 1996) . Enhanced RI promoter activity ( Figure 5 ) as well as the increased binding of nuclear proteins to the 32 P-labeled Sp1 oligonucleotides ( Figure  6b ,c) in the 5 aza C-treated GEO cells indicate that increased Sp1 activity was induced by 5 aza C. Thus, the results presented in this study indicate that reduced or low levels of Sp1 activity results in transcriptional repression of RI in GEO human colon carcinoma cells. This appears to have a role in uncontrolled growth and subsequent malignant progression as evidenced by studies demonstrating that RI replacement reverses malignancy in GEO cells (Wang et al., 1996) . 5 aza C treatment has been reported to increase Sp1 activity without altering protein expression leading to TGF-a transcription of melanoma cells (Shin et al., 1992) . In c Figure 8 Sp1 stability in control and 5 aza C-treated GEO cells: Control (a) and 5 aza C-treated GEO cells (b) were treated with 10 mg/ml of cyclohexamide, and cells were harvested at the indicated time points to isolate nuclear extracts. Nuclear extracts (10 mg) were resolved on a 7.5% SDS ± PAGE, transferred to nitrocellulose membrane, and probed with rabbit anti-human Sp1 polyclonal antibody. (c) The Alpha Imager system was used to quantitate Sp1 protein half-life under control and 5 aza C treatment conditions a b Figure 9 Eect of exogenous Sp1 on the RI promoter activity and RI expression: (a) GEO RI-Luc cells were transiently transfected with Sp1 cDNA as described under Materials and methods. Cells were harvested at 60 h following transfection and luciferase activity was determined and presented as relative units. (b) Total RNA was isolated from control and Sp1 cDNA transfected GEO cells and RI transcript levels were analysed using RNase protection assay as described under Materials and methods. RNA from the TGF-b responsive human colon carcinoma cell line, FET was used as a positive control and t-RNA as a negative control our study, 5 aza C-treated GEO cells did not show any increase in the Sp1 transcript levels (data not shown). Hence, Sp1 induction as a result of the demethylation at the Sp1 gene locus was eliminated.
However, 5 aza C-treated GEO cells exhibited enhanced steady state levels of Sp1 nuclear protein ( Figure 7 ) and protein stability determination after cyclohexamide treatment revealed a signi®cant increase in the protein half-life from 5 aza C-treated GEO nuclear extracts compared with untreated control extracts (Figure 8 ). RII transcription is also dependent upon Sp1 (Ammanamanchi et al., 1998) . Sp1 protein half-life increase was also observed in 5 aza-2' dc treated breast cancer cells leading to regeneration of de®cient RII transcription and TGFb response (Ammanamanchi et al., 1998) . The mechanism for increased stability of Sp1 is not clear. Sp1 undergoes post-translational modi®cations such as phosphorylation and glycosylation (Jackson et al., 1990; Jackson and Tjian, 1988) . Glycosylation may aid in nuclear localization and DNA binding while phosphorylation may assist in stabilizing the Sp1-DNA complex. Glycosylation has been reported to stabilize Sp1 (Han and . However, modeling studies suggested that glycosylation of Sp1 adversely aects protein-protein interactions (Roos et al., 1997) . Thus, the 5 aza C aected gene resulting in Sp1 protein stabilization is probably not aecting glycosylation. In our study, transfection of Sp1 cDNA into GEO cells increased RI promoter activity and induced RI expression (Figure 9a,b) . This con®rms further that low Sp1 levels/activities contribute to RI repression in GEO cells. However, the overall transcription could also be aected by changes in repressor proteins. This is a novel mechanism of RI repression in human colon carcinoma cells leading to TGF-b resistance and based on previous studies, one which can contribute to malignant progression (Wang et al., 1996) .
It is interesting to note that RII levels appear to be adequate for TGF-b response in GEO cells since ectopic RII expression does not lead to increased TGFb sensitivity in these cells. Thus, in contrast to breast cancer cells (Ammanamanchi et al., 1998 ) Sp1 de®ciency does not appear to aect RII function in GEO cells when RI is limiting. However, increased Sp1 protein levels following 5 aza C treatment in GEO cells elevated RII expression. In addition, 5 aza C mediated Sp1 expression also up-regulated Sp1 dependent Cyclin A and p21/waf1/cip1 promoter activities in Sp1 de®cient GEO colon cancer cells as well as MCF-7L breast cancer cells. Thus, Sp1 de®ciency appears to aect the expression of a variety of promoters.
Materials and methods
Cell culture
The GEO human colon carcinoma cell line was established in vitro from a primary tumor (Brattain et al., 1984) . Cells were maintained at 378C in a humidi®ed atmosphere of 5% CO 2 in McCoy's 5A serum-free medium supplemented with pyruvate, vitamins, amino acids, antibiotics, 10 ng/ml epidermal growth factor, 20 mg/ml insulin and 4 mg/ml transferrin. MCF-7L cells were obtained from American Type Culture Collection (ATCC) and were grown in McCoy's 5A medium a b Figure 10 5 aza C mediated Sp1 eects on multiple Sp1 dependent promoters: (a) Untreated or 5 aza C-treated GEO colon cancer cells were transiently transfected with Sp1 dependent RII-Luc, Cyclin A-Luc and p21/waf1/cip1-Luc constructs and non-Sp1 dependent pNFkB-Luc construct as described under Materials and methods. Luciferase activity was determined at 60 h following transfection. (b) Untreated or 5 aza C-treated MCF-7L breast cancer cells were transiently transfected with Sp1 dependent RI-Luc, Cyclin A-Luc and p21/waf1/cip1-Luc constructs and non-Sp1 dependent pNFkB-Luc construct as described under Materials and methods. Luciferase activity was measured at 60 h following transfection supplemented with 10% fetal bovine serum. Cells were seeded at a density of 4610 5 cells per 10 cm culture dish (day 0) for experiments in which 5 aza C (Sigma, St. Louis, USA) was used. The drug was added to growth medium (2 mg/ml, unless indicated otherwise) in two 24 h pulses on days 2 and 5. Cells were used on day 8 for RNA determinations, receptor binding studies, transfections or isolation of nuclear extracts for mobility shift assays (EMSA) and Sp1 Western immunoblots.
Nuclear run-on assay
Isolation of nuclei and nulear run-on assays were performed as described previously (Periyasamy et al., 1996) . Brie¯y, GEO, CBS 4 and CBS 9 cells were lysed and the nuclei were pelleted by brief centrifugation. The pellet was re-suspended in 200 ml reaction buer (150 mM potassium acetate, 10 mM MgCl 2 , 0.1 mM DTT, 50 mM HEPES [pH 8.0], 10% glycerol, 0.5 mM each of ATP, CTP, GTP, 13 mM UTP, and 100 mci of [a-32 P] UTP [3000 ci/mmol Dupont, NEN]) and incubated for 30 min at 308C. The 32 P-labeled RNA was isolated by cesium gradient centrifugation and an equal amount of radioactivity in 5 ml hybridization buer was added to each ®lter and incubated for 2 days at 458C. Filters were prepared using the Schleicher and Schuell slot blot system. Each slot was loaded with 10 mg of linearized, alkali-denatured plasmid and then washed with 1 M ammonium acetate. The RI plasmid contained a 2.35 kb linearized EcoRI-SalI cDNA fragment and vector without RI insert was used as a control. The plasmid DNA was immobilized on nitrocellulose ®lters by baking at 808C for 1.5 h in a vacuum oven. After hybridization, ®lters were washed twice in 26SSPE (sodium chloride, sodium phosphate and EDTA) solution at 458C for a total of 60 min and then transferred to 26SSPE solution containing RNase A (10 mg/ml) and incubated for 20 min at 378C, air-dried, and exposed to Kodak XAR-5 ®lm with intensifying screens.
RNA analysis
Total RNA from the GEO cells was extracted by guanidine thiocyanate homogenization and ultracentrifugation through a cesium gradient as described previously (Ammanamanchi et al., 1998) . RNase protection assays were performed as described previously (Ammanamanchi et al., 1998) . Brie¯y, radioactive riboprobe was allowed to hybridize overnight with the RI mRNA in 40 mg of total RNA. After RNase A and T1 treatment, the protected double-stranded RNA fragments were analysed by urea-PAGE and visualized by autoradiography. Actin was used to normalize sample loading.
Receptor cross-linking
Simian TGF-b1 was puri®ed and iodinated by the chloramine-T method (Ammanamanchi et al., 1998) . Cells were seeded at a density of 3610 4 /well in a six-well plate (day 0). Wherever indicated, 2 or 4 mg/ml of 5 aza C was added in two 24 h pulses on days 2 and 5, and receptor binding studies were carried out on day 8 using 200 pm of 125 I TGF-b as described previously (Ammanamanchi et al., 1998) . Labeled cells were solubilized in 200 ml of 1% Triton X-100 with 1 mm phenylmethylsulfonyl¯uoride. Equal amounts of cell lysate protein were separated by 4 ± 10% gradient SDS ± PAGE under reducing conditions and exposed for autoradiography.
Luciferase assay
The TGF-b responsive plasminogen activator inhibitor promoter-luciferase reporter construct (p3TP-Lux) and TGF-b RI promoter-luciferase reporter construct (RI-Luc) were used to determine TGF-b sensitivity and RI promoter activities, respectively (Bloom et al., 1996; Wrana et al., 1992) . The p3TP-Lux vector (15 mg) or TGF-b RI-Luc (15 mg) along with a hygromycin containing plasmid (2 mg) were stably transfected into GEO cells using a Bio-Rad electroporator at 250 mv and 960 microfarads. Hygromycin (100 mg/ml) resistant clones were selected, expanded and used to assay TGF-b sensitivity and RI promoter activity. GEO p3TP-Lux transfectants and RI-Luc transfectants are referred to as GEO p3TP cells and GEO RI-Luc cells, respectively. GEO p3TP cells and GEO RI-Luc cells were treated with 5 aza C in two 24 h pulses on days 2 and 5. After the treatment, cells were harvested on day 8 in 200 ml of lysis buer (Luciferase assay system, Promega). For the TGF-b sensitivity assay, GEO p3TP cells were treated with 5 ng/ml of TGF-b1 on day 7, prior to luciferase assay on day 8. The luciferase activity was measured in the ®rst 10 s after substrate addition using a luminometer (Berthold Lumat LB9501).
EMSA Double-stranded oligonucleotides representing two Sp1 sites (7159 bp and 7347 bp relative to start site) (Bloom et al., 1996) were custom designed and obtained from Genosys. The oligonucleotides were end labeled using g 32 P ATP and electrophoretic mobility shift assays were performed as described previously (Ammanamanchi et al., 1998) . For the super shift assay, the nuclear extract was incubated with 2 mg of Sp1 antibody (anti-rabbit, Santa Cruz) for 15 min on ice prior to the addition of 32 P-labeled oligonucleotide.
Western immunoblot analysis of Sp1
Nuclear extracts (4 mg) from 5 aza C-treated and untreated GEO cells were used to determine the Sp1 protein levels as described previously (Ammanamanchi et al., 1998) . The GEO cells were treated with 10 mg/ml of cyclohexamide and harvested at the indicated time points for the Sp1 protein stability studies (Mortensen et al., 1997) .
Transient transfections
The Sp1 cDNA vector (6 mg) or the CMV control vector without Sp1 cDNA (Shen et al., 1995) along with 2 mg of bgalactosidase plasmid were transiently transfected into GEO RILuc cells and GEO cells using the Fugene 6 chemical method (Boehringer Mannheim). Cells were harvested at 60 h following transfection and RI promoter activity was determined in the GEO RI-Luc cells using the luciferase assay (Luciferase assay system, Promega). RI transcript levels were determined by RNase protection assay in the GEO cells. RII-Luc, Cyc A-Luc and p21/waf1/cip1-Luc constructs (Choi et al., 1998; Datto et al., 1995; Yoshizumi et al., 1997) were used to determine TGF-b receptor type II (RII), Cyclin A and p21/waf1/cip1 promoter activities, respectively. The nonSp1 dependent promoter, pNFkB-Luc (Stratagene) was used as a control. The above mentioned vectors and bgalactosidase plasmid were transiently transfected into untreated and 5 aza C-treated GEO colon carcinoma and MCF-7L breast cancer cells using the Fugene 6 method (Boehringer Mannheim). Cells were harvested at 60 h following transfection and promoter activities were analysed by luciferase assays. Transfection eciencies were normalized to b-galactosidase (Ammanamanchi et al., 1998) .
